FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

NCT05217069 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Treatment Related Cancer

Interventions

DRUG: 5-FU
DRUG: Folinic Acid
DRUG: Irinotecan
DRUG: Cetuximab
DRUG: Avelumab

Sponsor

Ludwig-Maximilians - University of Munich

Collaborators

[object Object]
[object Object]